MedTrace Logo

Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients

NCT01543464 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-03-19

No results posted yet for this study

Summary

The aim of the study is to assess if treatment with IDO/Survivin peptide vaccine can enhance the efficacy of temozolomide chemotherapy in patients with metastatic malignant melanoma.

Conditions

  • Malignant Melanoma

Interventions

DRUG

Chemotherapy: Temozolomide

Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week

Sponsors & Collaborators

  • Copenhagen University Hospital at Herlev

    collaborator OTHER

  • Inge Marie Svane

    lead OTHER

Principal Investigators

  • Trine Zeeberg Iversen, MD · Center for Cancer ImmuneTherapy

  • Inge Marie Svane, MD, PhD, Prof. · Center for Cancer ImmunoTherapy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543464 on ClinicalTrials.gov